Prevalence of hepatitis C virus (HCV) infection and HCV genotypes of hemodialysis patients in Salvador, Northeastern Brazil

Silva, L. K.; Silva, M. B. S.; Rodart, Itatiana Ferreira; Lopes, Gisele Barreto; Costa, Fernando Quadros; Melo, Maria Elizabeth Lisboa de; E, Gusmão; Reis, Mitermayer Galvão dos

doi:10.1590/s0100-879x2006000500005

Cited by 32 publications

(28 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31,38 In comparison to other Brazilian studies, although our rates are consistent with fi ndings from some studies, 8,12 our results were lower than those reported by several other studies (PCR positivity between 69% and 100% in anti-HCV positive patients). 7,9,10,16,39,40 This may be partially explained by the fact that the PCR technique employed in the present study had a detection limit of 200 IU/mL, which is less sensitive in HD patients, who often present low or variable viral loads.…”

Section: Discussionmentioning

confidence: 87%

Hepatitis C in hemodialysis: the contribution of injection drug use

et al. 2010

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV) infection is the most common cause of acute or chronic hepatitis in patients on hemodialysis (HD). The purpose of this study was to describe the prevalence of positive HCV RNA and investigate injection drug use as an emerging risk factor in patients with chronic renal disease on HD. Methods: This was a multicenter cross-sectional study with 325 patients with chronic renal disease on HD in the period between August 1, 2005 to August 30, 2006, receiving care at four institutions in the city of Porto Alegre, Southern Brazil. Epidemiological data were collected by means of a structured questionnaire. The following laboratory tests were performed: alanine aminotransferase (ALT), anti-hepatitis C virus antibodies (anti-HCV), and qualitative polymerase chain reaction (PCR). Results: Of 325 patients, 68 had positive HCV RNA results. The comparison between patients with positive and negative PCR results revealed signifi cant differences in duration of HD (mean = 71 versus 52.4 months; p = 0.02); previous blood transfusion (92% versus 72%; p < 0.01); injection drug use (13% versus 0.7%; p < 0.01); anti-HCV positivity at start of HD therapy (60% versus 4%; p < 0.01); and mean ALT value (39 versus 26.5; p < 0.01). Logistic regression analysis showed a positive HCV RNA independently associated to being on HD for more than fi ve years [OR: 2.1 (95% CI 1.2 -3.8)]; previous blood transfusion [OR: 3.7 (95% CI 1.4 -9.5)]; and injection drug use [OR: 22.6 (95% CI 4.2 -119.6)]. Conclusion: Injection drug use was an independent risk factor for HCV infection among chronic renal disease patients on HD.

show abstract

Section: Discussionmentioning

confidence: 87%

Hepatitis C in hemodialysis: the contribution of injection drug use

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Neste estudo, os 35 (14,8%) pacientes anti-VHC positivos foram submetidos a pesquisa qualitativa do HCV-RNA por RT-PCR, que foi positiva nas duas amostras testadas em 25 (71,6%) pacientes. A proporção (71,6%) de pacientes anti-VHC positivo com replicação viral (infecção crônica pelo VHC) foi semelhante aos diversos estudos publicados na literatura (10,20,32,51,56) . Desta forma, 10,6% da amostra total (25/236) foram considerados portadores de infecção crônica pelo VHC.…”

Section: Discussionunclassified

Infecção pelo vírus da hepatite c em pacientes em hemodiálise: prevalência e fatores de risco

Leao

Pace

Chebli

2010

Arq. Gastroenterol.

View full text Add to dashboard Cite

RESUMO -Contexto -Doentes com doença renal crônica em tratamento hemodialítico apresentam risco aumentado de aquisição do vírus da hepatite C (VHC). Elevadas taxas de prevalência têm sido detectadas em unidades de diálise do mundo inteiro. Estudos recentes têm demonstrado que a infecção pelo VHC interfere de forma negativa na sobrevida dos pacientes em hemodiálise e naqueles submetidos ao transplante renal. Objetivos -Determinar a prevalência e os fatores de risco da infecção pelo VHC em pacientes submetidos a hemodiálise. INTRODUÇÃOPacientes com doença renal crônica (DRC) em hemodiálise (HD) são especialmente predispostos à contaminação pelo vírus da hepatite C (VHC). Estudos realizados no mundo inteiro demonstram que, apesar das diversas medidas adotadas nas unidades de HD, a infecção pelo VHC continua prevalente. O VHC constitui-se hoje na principal causa de doença hepática entre os doentes com DRC em tratamento dialítico (4,38,57,59) . A prevalência da infecção pelo VHC nas unidades de HD varia conforme o país em estudo. Na Holanda, 3% dos indivíduos em HD têm hepatite C, enquanto na Moldávia 75% dos doentes com DRC em HD apresentam infecção pelo VHC. Geralmente, taxas mais elevadas são observadas em países em desenvolvimento (12,25,27,46,51) . O censo da Sociedade Brasileira de Nefrologia de 2007 mostrou que a prevalência média do anti-VHC nas unidades de hemodiálise do Brasil foi de 9,1% (55) , mas estudos publicados nos últimos anos mostram taxas variáveis, com prevalências de 12% e 52% nos pacientes com DRC em unidades de diálise de Belo Horizonte e Fortaleza, respectivamente (37,43) . Entre os doentes com DRC em HD, diversos fatores de risco envolvidos na infecção pelo VHC têm sido identificados. Dentre os principais, figura a transfusão de sangue, o tempo de HD, a modalidade de diálise (HD

show abstract

“…In Brazil, several studies have been conducted to determine the distribution of HCV genotypes among different groups of individuals. Most of these studies have shown a predominance of genotype 1 (Krug et al 1996, Oliveira et al 1999, Paraná et al 2000, Busek & Oliveira 2002, Codes et al 2003, Vogler et al 2004, Martins et al 2006, Silva et al 2006. The aim of the present study was to determine with precision the frequency of each HCV genotype in the South of Brazil, by studying a large cohort of patients from Rio Grande do Sul (RS) and Santa Catarina (SC), the southernmost states of the country.…”

mentioning

confidence: 92%

High proportion of hepatitis C virus genotypes 1 and 3 in a large cohort of patients from Southern Brazil

Silva

Costi

Krug³

et al. 2007

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Hepatitis C virus (HCV) isolates have been divided into six genotypes (1 to 6). The duration of hepatitis C standard treatment is 48 weeks for patients infected with HCV genotype 1 vs 24 weeks for those infected with genotypes 2 and 3. A total of 1544 HCV isolates from chronic patients living in the southern Brazilian states of Rio Grande do Sul (RS, n = 627) and Santa Catarina (SC, n = 917) were genotyped by restriction fragment length polymorphism (RFLP) of polymerase chain reaction (PCR) products. In RS, 338 (53.9%; 34 (5.4%; 255 (40.7%;.6%) samples were from genotypes 1, 2, and 3, respectively. In SC, 468 (51%; 26 (2.9%; 423 (46.1%; samples were from genotypes 1, 2, and 3, respectively. Genotyping results were confirmed by direct nucleotide sequencing of PCR products derived from 68 samples, without any discrepancy between PCR-RFLP and nucleotide sequencing methods. In conclusion, almost half of the hepatitis C patients from South of Brazil are infected by genotypes 2 and 3 and, these results have important consequential therapeutic implications as they can be treated for only 24 weeks, not 48.Key words: hepatitis C virus genotypes -polymerase chain reaction -restriction fragment lengh polymorphismnucleotide sequencing -Rio Grande do Sul -Santa CatarinaChronic hepatitis C, caused by infection with hepatitis C virus (HCV), is a global health problem, with more than 170 million infected individuals worldwide (WHO 1999). In 15 -20% of acute HCV infections, the patients recover spontaneously. However, in a large majority of cases, the disease runs a chronic course, clinically silent. Persistent infection may lead to severe liver diseases, such as cirrhosis and hepatocellular carcinoma, which require intensive treatment regimens and, in some cases, liver transplantation, and long-term care.HCV is primarily transmitted by the parenteral route. Sexual and perinatal transmissions have also been demonstrated, although less frequent (Poupon 2005). Since there is no available vaccine against hepatitis C, the only means to lower the disease burden are prevention of new infections and treatment of chronic carriers.HCV has a large genetic heterogeneity. Virus isolates have been classified into six genotypes (1 to 6), based on nucleotide sequence divergence of 30 -35% (Simmonds 2004). Genotypes 1, 2, and 3 circulate around the world, while genotypes 4, 5, and 6 are restricted to determined geographical areas (McOmish et al. 1994). In Brazil, genotypes 1, 2, and 3 predominate, although genotypes 4 and 5 have also been found (Campiotto et al. 2005).HCV genotype determination is necessary to define the optimal duration of therapy and the likelihood of response. According to the European Association for the Study of the Liver (EASL 1999) International Consensus Panel and National Institutes of Health (NIH 2002) Consensus Panel on management of hepatitis C, standard therapy for chronic HCV infection is based on combination of pegylated interferon (PEG IFN) alfa-2a or alfa-2b with ribavirin (RBV) during 48 weeks for patie...

show abstract

Prevalence of hepatitis C virus (HCV) infection and HCV genotypes of hemodialysis patients in Salvador, Northeastern Brazil

Cited by 32 publications

References 33 publications

Hepatitis C in hemodialysis: the contribution of injection drug use

Hepatitis C in hemodialysis: the contribution of injection drug use

Infecção pelo vírus da hepatite c em pacientes em hemodiálise: prevalência e fatores de risco

High proportion of hepatitis C virus genotypes 1 and 3 in a large cohort of patients from Southern Brazil

Contact Info

Product

Resources

About